Rapid and sustained immune tolerance to inhibitors induced by a plasma‐derived, VWF‐containing FVIII concentrate
- 29 January 2019
- journal article
- letter
- Published by Wiley in Haemophilia
- Vol. 25 (2), E110-E113
- https://doi.org/10.1111/hae.13676
Abstract
No abstract availableThis publication has 9 references indexed in Scilit:
- Recombinant factor VIII Fc fusion protein for immune tolerance induction in patients with severe haemophilia A with inhibitors-A retrospective analysisHaemophilia, 2018
- Many factor VIII products available in the treatment of hemophilia A: an embarrassment of riches?Journal of Blood Medicine, 2017
- Postmarket Safety Events Among Novel Therapeutics Approved by the US Food and Drug Administration Between 2001 and 2010Jama-Journal Of The American Medical Association, 2017
- Immune tolerance induction in patients with haemophilia a and inhibitors: effectiveness and cost analysis in an European Cohort (The ITER Study)Haemophilia, 2015
- Management of Haemophilia in Developing Countries: Challenges and OptionsIndian Journal of Hematology and Blood Transfusion, 2015
- Adult haemophilia A patients with inhibitors: successful immune tolerance induction with a single FVIII/VWF productHaemophilia, 2014
- Primary and rescue immune tolerance induction in children and adults: a multicentre international study with a VWF‐containing plasma‐derived FVIII concentrateHaemophilia, 2013
- International workshop on immune tolerance induction: consensus recommendations1Haemophilia, 2007
- Immune tolerance induction with a high purity von Willebrand factor/VIII complex concentrate in haemophilia A patients with inhibitors at high risk of a poor responseHaemophilia, 2007